Replies to post #43779 on Biotech Values

[AlpineBV_Miller]

"There may be no such confounding in these trials but it's still a bad design for pivotal trials in first-in-class drugs , IMO."

You mean like inert placebo for Nexavar and Sutent?

[walldiver]

DNDN crossovers-We do have the two-year median survival for the 9901 trial from Sept 2003:

Provenge arm 26.3 months
placebo crossovers 23.9 months
placebo noncrossovers 19.3 months

I would imagine that the final data was fairly similar...and I would also imagine that the 9902A median survival breakdown would have had a similar, laddered improvement from placebo noncrossovers-->placebo crossovers-->Provenge arm